Studieoverzicht

 
 
 
  2022-03 ALPHABET       Open       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2018-01 TRAIN-3       Follow up       Neoadjuvant       HER2+, any HR       Not applicable  
  2013-03 PERNETTA       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2012-03 TRAIN-2       Follow up       Neoadjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2012-02 SafeHer       Follow up       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2011-02 APHINITY       Follow up       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2008-03 HAT       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2007-01 ALTTO       Closed       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2004-02 TBP       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2002-04 HERA       Closed       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2002-02 Hertax       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal